Literature DB >> 27687988

One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.

Wataru Matsumiya1, Shigeru Honda2, Keiko Otsuka2, Akiko Miki2, Takayuki Nagai2, Hisanori Imai2, Sentaro Kusuhara2, Makoto Nakamura2.   

Abstract

PURPOSE: The purpose of the study was to evaluate the 1-year visual and anatomical outcomes of combination therapy with intravitreal aflibercept (IVA) and verteporfin photodynamic therapy (vPDT) for polypoidal choroidal vasculopathy (PCV), and to determine the predictors of a good visual outcome.
METHODS: This was a prospective case-series study. Twenty eyes from 20 treatment-naïve PCV patients were treated with combination therapy with IVA and vPDT. Best-corrected visual acuity (BCVA) and morphological parameters including polypoidal lesions in indocyanine green angiography (ICGA) were evaluated over 12 months of follow-up.
RESULTS: The mean logMAR BCVA was significantly improved from 0.30 at baseline to 0.20 at 3 months and 0.18 at 12 months. The mean central retinal thickness was also significantly improved at 3 months and at 12 months. In ICGA, complete regression of polypoidal lesions was found in 14 out of 20 eyes (70 %) at 3 months and in 14 out of 18 eyes (78 %) at 12 months although no ICGA were done on two eyes. In the multivariate logistic regression analyses, the baseline greatest linear dimension was found as a significant predictive factor for good visual improvement (≧0.3 LogMAR units improvement from baseline) at 12 months.
CONCLUSION: In this study, combination therapy with IVA and vPDT gave visual and anatomical improvements to treatment-naïve PCV patients over 12 months of follow-up period.

Entities:  

Keywords:  Aflibercept; Combination therapy; One-year outcome; Polypoidal choroidal vasculopathy; Polypoidal lesion; Verteporfin photodynamic therapy

Mesh:

Substances:

Year:  2016        PMID: 27687988     DOI: 10.1007/s00417-016-3500-1

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  29 in total

1.  Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy.

Authors:  Hae Min Kang; Hyoung Jun Koh
Journal:  Am J Ophthalmol       Date:  2013-07-24       Impact factor: 5.258

2.  EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.

Authors:  Adrian Koh; Won Ki Lee; Lee-Jen Chen; Shih-Jen Chen; Yehia Hashad; Hakyoung Kim; Timothy Y Lai; Stefan Pilz; Paisan Ruamviboonsuk; Erika Tokaji; Annemarie Weisberger; Tock H Lim
Journal:  Retina       Date:  2012-09       Impact factor: 4.256

3.  Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.

Authors:  Peter K Kaiser; David S Boyer; Alan F Cruess; Jason S Slakter; Stefan Pilz; Annemarie Weisberger
Journal:  Ophthalmology       Date:  2012-03-22       Impact factor: 12.079

4.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

5.  Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy.

Authors:  R F Spaide; L A Yannuzzi; J S Slakter; J Sorenson; D A Orlach
Journal:  Retina       Date:  1995       Impact factor: 4.256

6.  Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy.

Authors:  Eriko Akaza; Ryusaburo Mori; Mitsuko Yuzawa
Journal:  Retina       Date:  2008-05       Impact factor: 4.256

7.  Photodynamic therapy versus combination therapy in polypoidal choroidal vasculopathy: changes of aqueous vascular endothelial growth factor.

Authors:  Mee Yon Lee; Won Ki Lee; Jiwon Baek; Oh Woong Kwon; Jin Hae Lee
Journal:  Am J Ophthalmol       Date:  2013-05-09       Impact factor: 5.258

8.  Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Authors:  Jeffrey S Heier; David M Brown; Victor Chong; Jean-Francois Korobelnik; Peter K Kaiser; Quan Dong Nguyen; Bernd Kirchhof; Allen Ho; Yuichiro Ogura; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Yuhwen Soo; Majid Anderesi; Georg Groetzbach; Bernd Sommerauer; Rupert Sandbrink; Christian Simader; Ursula Schmidt-Erfurth
Journal:  Ophthalmology       Date:  2012-10-17       Impact factor: 12.079

9.  Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.

Authors:  Nicholas Papadopoulos; Joel Martin; Qin Ruan; Ashique Rafique; Michael P Rosconi; Ergang Shi; Erica A Pyles; George D Yancopoulos; Neil Stahl; Stanley J Wiegand
Journal:  Angiogenesis       Date:  2012-06       Impact factor: 9.596

Review 10.  Combined intravitreal anti-VEGF and photodynamic therapy versus photodynamic monotherapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis of comparative studies.

Authors:  Wei Wang; Miao He; Xiulan Zhang
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

View more
  9 in total

1.  Indocyanine green angiography findings in patients with neovascular age-related macular degeneration refractory to ranibizumab switched to aflibercept.

Authors:  Cristina Calvo-Gonzalez; Juan Reche-Frutos; José Ignacio Fernández-Vigo; Juan Donate-López; Irene Serrano-García; Cristina Fernández-Pérez
Journal:  Int Ophthalmol       Date:  2019-02-14       Impact factor: 2.031

2.  Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial.

Authors:  Won Ki Lee; Tomohiro Iida; Yuichiro Ogura; Shih-Jen Chen; Tien Yin Wong; Paul Mitchell; Gemmy Chui Ming Cheung; Zhongqi Zhang; Sérgio Leal; Tatsuro Ishibashi
Journal:  JAMA Ophthalmol       Date:  2018-07-01       Impact factor: 7.389

3.  Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy.

Authors:  Tsutomu Sakai; Noriko Kato; Masaomi Kubota; Hiroshi Tsuneoka
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-06-11       Impact factor: 3.117

4.  Comparison of 3-year outcomes of photodynamic therapy combined with intravitreal ranibizumab or aflibercept for polypoidal choroidal vasculopathy in a European cohort.

Authors:  Siyin Liu; Ramandeep Chhabra
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-06-09       Impact factor: 3.535

5.  Association of an age-related maculopathy susceptibility 2 gene variant with the 12-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Shunichiro Nakai; Wataru Matsumiya; Akiko Miki; Shigeru Honda; Makoto Nakamura
Journal:  Jpn J Ophthalmol       Date:  2019-08-02       Impact factor: 2.447

6.  Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy.

Authors:  Wataru Kikushima; Yoichi Sakurada; Atsushi Sugiyama; Seigo Yoneyama; Naohiko Tanabe; Mio Matsubara; Fumihiko Mabuchi; Hiroyuki Iijima
Journal:  Sci Rep       Date:  2017-11-28       Impact factor: 4.379

7.  Comparison between 1-year outcomes of aflibercept with and without photodynamic therapy for polypoidal choroidal vasculopathy: Retrospective observation study.

Authors:  Kei Takayama; Hiroki Kaneko; Keiko Kataoka; Kyoko Hattori; Eimei Ra; Taichi Tsunekawa; Hiroshi Fukukita; Fuminori Haga; Yasuki Ito; Hiroko Terasaki
Journal:  PLoS One       Date:  2017-05-03       Impact factor: 3.240

8.  Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study.

Authors:  Kanji Takahashi; Masahito Ohji; Hiroko Terasaki; Shigeru Honda; Philippe Margaron; Tadhg Guerin; Mitsuko Yuzawa
Journal:  Clin Ophthalmol       Date:  2018-09-13

9.  One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Hsin-Yu Weng; Tzu-Lun Huang; Pei-Yao Chang; Jia-Kang Wang
Journal:  BMC Pharmacol Toxicol       Date:  2019-05-14       Impact factor: 2.483

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.